AbCellera Biologics (ABCL) Research & Development (2020 - 2023)
AbCellera Biologics (ABCL) has disclosed Research & Development for 4 consecutive years, with $48.6 million as the latest value for Q4 2023.
- For the quarter ending Q4 2023, Research & Development rose 72.14% year-over-year to $48.6 million, compared with a TTM value of $175.7 million through Dec 2023, up 62.83%, and an annual FY2024 reading of $167.3 million, down 4.78% over the prior year.
- Research & Development was $48.6 million for Q4 2023 at AbCellera Biologics, up from $37.9 million in the prior quarter.
- Across five years, Research & Development topped out at $52.6 million in Q1 2023 and bottomed at $4.1 million in Q1 2020.
- Average Research & Development over 4 years is $23.4 million, with a median of $21.9 million recorded in 2021.
- The sharpest move saw Research & Development surged 199.95% in 2021, then surged 36.68% in 2023.
- Year by year, Research & Development stood at $8.6 million in 2020, then surged by 99.27% to $17.2 million in 2021, then surged by 64.13% to $28.2 million in 2022, then skyrocketed by 72.14% to $48.6 million in 2023.
- Business Quant data shows Research & Development for ABCL at $48.6 million in Q4 2023, $37.9 million in Q3 2023, and $36.5 million in Q2 2023.